Streetbeat News

Earnings Revenues

LEMIF

Leading Edge Materials Corp. has released its quarterly financial results for the period ending January 31, 2025. The company, which trades on multiple exchanges including TSXV, Nasdaq First North, OTCQB, and Frankfurt Stock Exchange, has disclosed its financial performance for the quarter.

Portfolio Pulse from

March 21, 2025 | 10:15 pm

LEMIF

Leading Edge Materials Corp. has released its quarterly financial results for the period ending January 31, 2025. The company, which trades on multiple exchanges including TSXV, Nasdaq First North, OTCQB, and Frankfurt Stock Exchange, has disclosed its financial performance for the quarter.

Portfolio Pulse from

March 21, 2025 | 10:15 pm

ARWR

Arrowhead Pharmaceuticals (ARWR) is positioning itself as a leader in RNAi therapeutics with 19 clinical programs, including 4 phase 3 and 4 phase 2 trials. The company's drug plozasiran shows promising results in triglyceride reduction, with a key PDUFA date on November 18. A recent deal with Sarepta has extended the company's cash runway into 2028, providing financial stability.

Portfolio Pulse from

March 21, 2025 | 10:15 pm

MXG

Maxim Power Corp. (MXG) released its 2024 financial and operating results, reporting total revenue of $101 million and record annual generation from its M2 project. The company's audited financial statements and Management's Discussion and Analysis will be available on SEDAR+ and their website on March 21, 2025.

Portfolio Pulse from

March 21, 2025 | 10:00 pm

BN

Brookfield Property Partners has filed its 2024 annual report on Form 20-F with the SEC and Canadian securities authorities, including audited financial statements for the year ended December 31, 2024. The documents are available on their website and EDGAR/SEDAR+ platforms.

Portfolio Pulse from

March 21, 2025 | 10:00 pm

CIG

Companhia Energética de Minas Gerais (CEMIG) held its Q4 2024 earnings conference call, with key executives presenting the company's financial performance. The call featured top management including CEO Reynaldo Passanezi Filho and CFO Andrea Marques de Almeida discussing the company's results and strategic highlights.

Portfolio Pulse from

March 21, 2025 | 10:00 pm

ADMA

ADMA Biologics, an infectious disease drug developer, demonstrates promising financial performance with significant earnings and revenue growth. The company has a Zacks Rank #2 (Buy), with expected quarterly earnings of $0.16 per share (100% increase year-over-year) and revenue estimates of $119.1 million (45.5% year-over-year growth). Despite a 'D' valuation grade, the stock has returned 22.2% over the past month.

Portfolio Pulse from

March 21, 2025 | 10:00 pm

OSCR

Oscar Health (OSCR) demonstrates potential with 30.8% year-over-year quarterly revenue growth, impressive earnings trajectory, and an attractive 'A' value score. Despite a recent stock decline of 19.6%, the company shows promising financial indicators and maintains a Zacks Rank #3 (Hold).

Portfolio Pulse from

March 21, 2025 | 10:00 pm

MS

Morgan Stanley (MS) is experiencing a moderate performance with positive earnings and revenue forecasts. The investment bank has shown consistent earnings beats in the last four quarters, with a 10.4% expected earnings increase for the current quarter. However, the stock has underperformed the S&P 500 over the past month, returning -10.3%.

Portfolio Pulse from

March 21, 2025 | 10:00 pm

ACGL

Arch Capital Group (ACGL) demonstrates positive financial indicators, including a 21.1% year-over-year revenue growth forecast, consistent earnings beat history, and a value-oriented stock grade. Despite a projected earnings decline, the company maintains a stable market position with potential for investor interest.

Portfolio Pulse from

March 21, 2025 | 10:00 pm